ArticleBMC pediatrics2025
Clinical value of miR-200b in diagnosis and prognosis of childhood pneumonia.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Study on the value and mechanism of miR-369-5p in childhood pneumonia.BMC immunology · 2026Article
- Clinical significance and mechanistic study of SOX2-OT and miR-27b-3p expression in children with viral myocarditis.BMC pediatrics · 2026Article
- MIR210HG promotes the progression of pediatric pneumonia by inducing apoptosis and inflammation through downregulating miR-195-5p and upregulating FGF2.BMC pediatrics · 2026Article
- microRNA Biomarkers in Paediatric Infection Diagnostics-Bridging the Gap Between Evidence and Clinical Application: A Scoping Review.Non-coding RNA · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildhood pneumonia (CP) is a common respiratory infectious disease in children with high morbidity and mortality. However, differential changes in miRNAs may interact with the regulation of CP. The aim of this paper was to discuss the miR-200b expression in CP and its diagnostic and prognostic value.
methodsRT-qPCR was used to measure the miR-200b expression in venous blood. ROC curve was adopted to assess the diagnostic ability of miR-200b in children with CP. Logistic analysis was adopted to study the risk factors are related to CP. Kaplan-Meier was employed to analyze the prognostic ability of miR-200b in CP. Transfection of MRC-5 cells in vitro was used to verify the impact of miR-200b on cell proliferation and apoptosis.
resultsThe expression of miR-200b in serum of CP children was upregulated. ROC analysis prompted that upregulation of miR-200b could be effective in distinguishing between CP and healthy children. Compared with the good prognosis group, miR-200b expression was elevated in the poor prognosis group. Kaplan-Meier reminded that high expression of miR-200b led to a poor prognosis in CP. Cells experiments demonstrated that transfection with miR-200b inhibitor encouraged cell proliferation and inhibited apoptosis, whereas transfection with miR-200b mimic had the contrary result.
conclusionsmiR-200b had high diagnostic and prognostic value for children with CP and may become a biomarker for clinical diagnosis and prognosis. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.